Overview
This study is expected to enroll patients for a period of five years, with a total of 30 participants. It is a prospective observational study involving cancer patients with tumors having a longest diameter greater than or equal to 5 cm. Systemic drug therapy may be administered concurrently. The following inclusion criteria must be met for participation in the study: age greater than or equal to 18 years, Eastern Cooperative Oncology Group (ECOG) score ≤ 2, pathological confirmation of cancer diagnosis, tumor with a maximum diameter greater than or equal to 5 cm, one or more lesions, not suitable for surgery, patient has provided informed consent, patient receives SCART, and reproductive-age women must agree to take adequate contraceptive measures during the study and for six months after discontinuation of medication. The patient will receive a dose of 21 Gy in 3 fractions, with the dose maintained at 5 Gy per fraction for the entire tumor gross target volume (GTV) boundary. For certain patients, an additional two fractions of 5 Gy each were added using Stereotactic Body Radiotherapy (SBRT), resulting in a total dose of 5 Gy × 5 for the GTV boundary.
Eligibility
Inclusion Criteria:
- Age greater than or equal to 18 years
- ECOG score ≤ 2, pathological confirmation of cancer diagnosis
- Pathologically proved malignant tumor with a maximum diameter greater than or equal to 5 cm
- One or more lesions, not suitable for surgery
- Patient has provided informed consent
Exclusion Criteria:
- Pregnant
- Life expectancy less than six months
- Uncontrolled angina, arrythmia, and congestive heart failure
- History of malignant pleural effusion